Last reviewed · How we verify
CaCP29, a humanized monoclonal antibody
At a glance
| Generic name | CaCP29, a humanized monoclonal antibody |
|---|---|
| Sponsor | InflaRx GmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction (PHASE2)
- Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |